Why does beta blockers cause bronchospasm

Search for terms. Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. Last Update Posted : April 12, Study Description. Detailed Description:. Drug Information available for: Hydrocortisone acetate Hydrocortisone Hydrocortisone sodium succinate Propranolol hydrochloride Hydrocortisone cypionate Hydrocortisone valerate Hydrocortisone probutate Proctofoam-HC.

FDA Resources. Arms and Interventions. Participant then receives Histamine PC10 challenge, Administered 5mg Salbutamol via nebuliser, administered mcg Ipratropium Bromide via nebuliser; visit end. Outcome Measures. Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Inclusion Criteria: Ability to obtain Informed consent. Withhold LABAs, montelukast and theophyllines for 1 week prior to study.

Exclusion Criteria: Uncontrolled symptoms of asthma. Already a member or subscriber? Log in. Interested in AAFP membership? Learn more. Salpeter SR, et al. Ann Intern Med. November 5, ;—7. This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.

Contact afpserv aafp. Read the Issue. Sign Up Now. Mar 1, Issue. At trial's end, there were no significant differences between groups in airway hyperresponsiveness or asthma symptoms, although there was a 2. Beta blockers are a key component of care for people who have had previous heart attacks or who have systolic heart failure. Three beta blockers have demonstrated a survival benefit in systolic heart failure: the cardioselective agents metoprolol XL and bisoprolol, and the noncardioselective carvedilol.

It seems unlikely that the risks of worsening asthma or COPD outweigh the potential benefits of beta blocker use, in these patients. Beta blockers have not been proven beneficial in randomized trials for stable coronary artery disease primary prevention in people without a previous myocardial infarction or who have risk factors.

The theorized benefit among these patients drives the vast majority of beta-blocker prescriptions, but there is today no evidence-based imperative for this practice. What's more interesting is the question of whether chronic beta blocker use might actually improve asthma or COPD, as mounting observational evidence suggests. Enough safety data has accumulated that such prospective studies could be done ethically. There are a few small studies listed on clinicaltrials. We'll keep you posted.